Replies to post #217656 on Biotech Values

[poorgradstudent]

NKTR:

Yeah I'm not exactly sure what's going on there but haven't had time to relisten to the JPM presentation to seek clarity. Perhaps the 21 include those with prior lines of therapy and are therefore excluded from the treatment naive population shown later.